LEVOLET Trademark

Trademark Overview

On Wednesday, March 3, 2021, a trademark application was filed for LEVOLET with the United States Patent and Trademark Office. The USPTO has given the LEVOLET trademark a serial number of 90558860. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Monday, June 17, 2024. This trademark is owned by Genus Lifesciences Inc.. The LEVOLET trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical compositions containing levothyroxine or salts thereof for the treatment and prevention of thyroid disorders
levolet

General Information

Serial Number90558860
Word MarkLEVOLET
Filing DateWednesday, March 3, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateMonday, June 17, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 26, 2022

Trademark Statements

Goods and ServicesPharmaceutical compositions containing levothyroxine or salts thereof for the treatment and prevention of thyroid disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, June 3, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGenus Lifesciences Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressAllentown, PA 18102
Party NameGenus Lifesciences Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressAllentown, PA 18102

Trademark Events

Event DateEvent Description
Saturday, March 6, 2021NEW APPLICATION ENTERED
Thursday, June 3, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, September 24, 2021ASSIGNED TO EXAMINER
Tuesday, September 28, 2021NON-FINAL ACTION WRITTEN
Tuesday, September 28, 2021NON-FINAL ACTION E-MAILED
Tuesday, September 28, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, March 22, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, March 22, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 23, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, March 24, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 6, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 26, 2022PUBLISHED FOR OPPOSITION
Tuesday, April 26, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 21, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, December 14, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, December 14, 2022SOU EXTENSION 1 FILED
Wednesday, December 14, 2022SOU EXTENSION 1 GRANTED
Friday, December 16, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 15, 2023SOU TEAS EXTENSION RECEIVED
Thursday, June 15, 2023SOU EXTENSION 2 FILED
Thursday, June 15, 2023SOU EXTENSION 2 GRANTED
Saturday, June 17, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 21, 2023SOU TEAS EXTENSION RECEIVED
Thursday, December 21, 2023SOU EXTENSION 3 FILED
Thursday, December 21, 2023SOU EXTENSION 3 GRANTED
Saturday, December 23, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 17, 2024SOU TEAS EXTENSION RECEIVED
Monday, June 17, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 17, 2024SOU EXTENSION 4 FILED
Monday, June 17, 2024SOU EXTENSION 4 GRANTED

Related Keywords

levolet treatment prevention thyroid disorders thereof salts compositions containing levothyroxine pharmaceutical